Rematiq is a technology company.
Rematiq has raised $6.0M across 1 funding round.
Rematiq has raised $6.0M in total across 1 funding round.
Rematiq has raised $6.0M in total across 1 funding round.
Rematiq's investors include Project A Ventures, Singular, Christian Reber.
REMATIQ is a Berlin-based technology company founded in 2023 that builds an AI-powered platform for automated product compliance and requirements management in MedTech and life sciences. It serves medical device companies and innovators by transforming complex regulatory documents—like MDR and FDA guidelines—into structured, actionable data, automating workflows to slash documentation time by up to 90% and free engineers from paperwork.[1][2][3][4] This solves the core problem of regulatory complexity slowing innovation, enabling faster development of life-saving technologies while ensuring compliance and traceability across the product lifecycle.[1][3][5]
The company recently raised €5.4 million in Seed funding led by Project A Ventures, with participation from Amino Collective, HelloWorld, and angels like Boris Lokschin, to enhance its AI tech, grow its engineering team, and expand in Europe and the U.S.[2] Early traction includes partnerships with major MedTech manufacturers, positioning REMATIQ for rapid growth in a sector where R&D teams lose 40% of time to compliance burdens.[3]
REMATIQ was founded in 2023 by David Boutellier and Florian Scherer, experienced builders of medtech and AI products who faced regulatory hurdles firsthand.[1][2] Frustrated by fragmented requirements, unclear expectations, and shifting global standards that inflated costs and delayed progress, they launched the company to empower innovators.[1]
The idea emerged from their direct experience: years of navigating these challenges convinced them that AI could cut through the "regulatory noise" without compromising safety.[1][2] Pivotal early momentum came via Seed funding in 2025 and quick adoption by large MedTech firms, validating their vision of turning compliance into a strategic edge.[2][3]
REMATIQ rides the AI-for-regulated-industries wave, targeting MedTech's exploding compliance demands amid growing global regs like MDR/FDA updates.[1][2][3] Timing is ideal: regulatory volume/complexity surges while AI maturity enables real-time automation, turning a "necessary evil" into a competitive moat for faster market entry and R&D acceleration.[3]
Market forces favor it—life sciences face chronic delays (projects abandoned pre-start), but AI integration into workflows unlocks efficiency, as seen in early large-client wins.[3] REMATIQ influences the ecosystem by redefining compliance as innovation fuel, speeding life-saving tech to patients and inspiring similar shifts in manufacturing/life sciences.[1][3][5][6]
REMATIQ is primed to dominate AI-driven regulatory tech, with Seed capital fueling AI advancements, team growth, and transatlantic expansion amid tailwinds like AI adoption in healthcare.[2] Trends like stricter post-market surveillance and AI-system regs will amplify demand, potentially evolving it into a full lifecycle platform for life sciences.
Its influence could expand by setting compliance standards, empowering more innovators to prioritize breakthroughs over bureaucracy—echoing the founders' mission to deliver patient solutions faster.[1][3]
Rematiq has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Seed in April 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2025 | $6.0M Seed | Project A Ventures, Singular, Christian Reber |